ArticleMMWR. Morbidity and mortality weekly report2025
Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024.
Article in MMWR. Morbidity and mortality weekly report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Global trends in pediatric Mycoplasma pneumoniae pneumonia research.Pediatric research · 2026Article
- Trends and outcomes ofMicrobiology spectrum · 2026Article
- Effects of a diagnostic stewardship intervention to de-implement widespread use of a rapid respiratory multiplex PCR test.Microbiology spectrum · 2026Article
- Health system implementation of clinical decision support to optimize respiratory pathogen profile utilization.Journal of clinical microbiology · 2026Article
- Clinical and laboratory features of pediatric Mycoplasma pneumoniae Pneumonia with viral versus bacterial co-infection.Italian journal of pediatrics · 2026Article
- Serum IL-6, IL-8, and Th/Ts ratio for severity assessment and short-term clinical outcome risk stratification in pediatric Mycoplasma pneumoniae pneumonia: insights into inflammation-immune imbalance.European journal of pediatrics · 2026Article
- Characteristics and influencing factors of bronchoalveolar lavage fluid cellular patterns in children withTranslational pediatrics · 2026Article
- Novel inflammatory biomarkers and disease severity in hospitalized children withTranslational pediatrics · 2026Article
- Reconstructing the post-pandemic landscape: a retrospective, hospital-based surveillance of respiratory pathogens in hospitalized children in Chenzhou, China, 2021-2025.BMC infectious diseases · 2026Article
- [Association between heparin-binding protein and other clinical indicators with the microscopic severity ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Clinical characteristics, risk factors, and pathogen spectrum of mixed infections in children withMicrobiology spectrum · 2026Article
- Article
- Long-term burden, trends, and inequality of lower respiratory infections attributable toTranslational pediatrics · 2026Article
- Coinfection Patterns ofInternational journal of molecular sciences · 2026Article
- Article
- Impact of pathogen co-detection on disease severity and clinical outcomes in children with Mycoplasma pneumoniae pneumonia.World journal of pediatrics : WJP · 2026Article
- Risk factors for plastic bronchitis in children with community-acquired pneumonia: a retrospective bronchoscopy-based study.BMC pulmonary medicine · 2026Article
- Impact of Allergic Diseases or Obstructive Sleep Apnea Risk on SevereJournal of clinical medicine · 2026Article
- Asyndromic surveillance of New York City emergency department diagnoses with the tree-temporal scan statistic.Journal of public health research · 2026Article
- A Challenging Presentation ofClinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae is a common bacterial cause of respiratory infection and a leading cause of childhood community-acquired pneumonia (CAP). Increases in M. pneumoniae infection occur every 3-5 years. In the United States, M. pneumoniae prevalence decreased during and immediately after the COVID-19 pandemic. Information from 42 U.S. children's hospitals that provided information to the Pediatric Health Information System, a database of clinical and resource use information, was used to identify discharge diagnostic codes for 2018-2024 indicating M. pneumoniae infection. M. pneumoniae-associated CAP incidence among children aged ≤18 years was significantly higher in 2024 (12.5 per 1,000 hospitalizations) than during 2018-2023 (2.1). During the study period, an M. pneumoniae diagnostic code was listed in 11.5% of pediatric CAP hospitalizations, peaking at 53.8% in July 2024. Among pediatric M. pneumoniae CAP cases, the highest percentage occurred among children aged 6-12 years (42.6%), followed by children aged 2-5 years (25.7%) and 13-18 years (21.1%). The lowest occurred among those aged 12-23 months (6.4%) and 0-11 months (4.2%). M. pneumoniae infections in 2024 were not more severe than 2018-2023 infections, as assessed by length of hospitalization and percentage of patients admitted to an intensive care unit. The increase in M. pneumoniae infections in the United States in 2024 might be higher than previous periodic increases because the susceptible population was larger after sustained low incidence during and immediately after the COVID-19 pandemic. Health care providers should be aware of the periodicity of M. pneumoniae CAP and consider testing for this pathogen as a cause of respiratory illness among children of all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.